• Broad spectrum

    of products for

    your industry

α-2,3-Sialyltransferase, rec.

human, expressed in HEK-293F, solution

For life science research only. Not for use in diagnostic procedures.

expand | collapse
Order information
α-2,3-Sialyltransferase, rec. material number and pack size:
Material Number Pack Size
07429916103 custom fill
Unit of measure is "mg".
α-2,3-Sialyltransferase, rec. can be used for in vitro glycoengineering of glycoproteins, e.g. therapeutic proteins.
α-2,3-Sialyltansferase, rec. is a highly active recombinant human glycosyltransferase, expressed in HEK-293F.
Benefits of using in vitro glycoengineering to modify glycosylation of therapeutic proteins:
  • Time- and cost-saving generation of glycan variants to facilitate drug development.
  • Optimized glycosylation without compromising other CQAs or product yield.
  • Improved lot-to-lot consistency to reduce risk of product quality variation and resulting delays.
  • Generation of glycoprofiles which may not otherwise be generated.
  • Streamlined analytics in comparability studies.
Incubation of α-2,3-Sialyltansferase and CMP-NANA with a glycoprotein leads to increased sialylation of the glycoprotein.

As α-2,3-Sialyltansferase rec. adds sialic acid only to galactosylated glycostructures, a galactosylation of the glycoprotein in a previous step helps to achieve higher sialylation levels. Galactosylation can be achieved by incubation of the target protein with ß-1,4-Galactosyltransferase and UDP-Galactose.
Molar mass: 34.5 kDa by cDNA
Appearance: Clear, colorless to slightly colored solution.
Composition: 50 mM MES, 200 mM NaCl, pH 6.4 ± 0.1 at +4°C
Specific activity: ≥80 U/μg
Protein A280nm ( 1 mg/mL) = 0.877: 5.5 ± 0.5 mg/mL
Purity: ≥90%
Bioburden: ≤100 CFU/mL (in evaluation)
Endotoxin: ≤10 EU/mg (in evaluation)
Stability: At -15 to -25°C within specification range for 12 months.
License disclaimer

78:The sale of the Product does not exhaust or grant any rights in third party patents including patents of companies of the F. Hoffmann - La Roche AG group of companies, in particular, for the use of modified antibodies obtained by using the product.